Skip to main content

Table 2 Number of patients with drug-related adverse events

From: A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

  Total (n = 27) 100 mg (n = 9) 250 mg (n = 9) 500 mg (n = 9)
Rang 1.35–1.89 mg/kg Rang 3.65–6.25 mg/kg Rang 6.41–11.11 mg/kg
Grade 1/2 No. (%) Grade 3/4 No. (%) Grade 1/2 No. (%) Grade 3/4 No. (%) Grade 1/2 No. (%) Grade 3/4 No. (%) Grade 1/2 No. (%) Grade 3/4 No. (%)
Fever 16 (59.3) 0 5 (55.6) 0 3 (33.3) 0 8 (88.9) 0
Transit increased ALT/AST 6 (22.2) 0 1 (11.1) 0 3 (33.3) 0 2 (22.2) 0
Chills 5 (18.5) 0 2 (22.2) 0 2 (22.2) 0 1 (11.1) 0
Arrhythmia 5 (18.5) 1 (3.7) 2 (22.2) 0 2 (22.2) 1 (11.1) 0 0
Fatigue 4 (14.8) 0 1 (11.1) 0 2 (22.2) 0 1 (11.1) 0
Dyspnea 4 (14.8) 0 1 (11.1) 0 3 (33.3) 0 0 0
Arthralgia 4 (14.8) 0 2 (22.2) 0 2 (22.2) 0 0 0
Nausea/vomiting 3 (11.1) 0 1 (11.1) 0 2 (22.2) 0 0 0
Palpitation 3 (11.1) 0 1 (11.1) 0 2 (22.2) 0 0 0
Headache 2 (7.4) 0 2 (22.2) 0 0 0 0 0
Dry mouth 2 (7.4) 0 1 (11.1) 0 0 0 1 (11.1) 0
Rash 2 (7.4) 0 1 (11.1) 0 1 (11.1) 0 0 0